Cubist Pharmaceuticals disclosed this week in a regulatory filing with the Securities and Exchange Commission that it is under investigation by the SEC and Department of Justice for potential violations of the Foreign Corrupt Practices Act.

Learn More
Already a member? Sign in to an existing account.

Jaclyn Jaeger is a freelance contributor to Compliance Week after working for the company for 15 years. She writes on a wide variety of topics, including ethics and compliance, risk management, legal,...